Scheduled Conferences, Product Breakthroughs, and Approvals - Research Report on Mylan, Baxter, Actavis, Thermo Fisher, and BD
NEW YORK, November 11, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Mylan Inc. (NASDAQ:MYL), Baxter International Inc. (NYSE:BAX), Actavisplc (NYSE:ACT), Thermo Fisher Scientific Inc. (NYSE:TMO), and Becton, Dickinson and Co. (NYSE:BDX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Mylan Inc. Research Report
On November 6, 2013, Mylan Inc. (Mylan) announced that it will present at the 2013 Credit Suisse Healthcare Conference on Wednesday, November 13, 2013 at 4:00 p.m. ET at the Phoenician Resort in Scottsdale, Arizona. The Company stated that the conference will be webcast live and can be accessed via its Investor Relations website. Mylan added that an archive of the webcast will be available approximately one hour after the live presentation concludes and can be accessed on its website for a limited time. The Full Research Report on Mylan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/5a20_MYL]
Baxter International Inc. Research Report
On October 31, 2013, Baxter International Inc. (Baxter) announced that the Company has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA)for the approval of RIXUBIS, recombinant factor IX (nonacog gamma) for the treatment and prophylaxis of bleeding in patients of all ages with Hemophilia B (also known as Christmas disease). Baxter added that RIXUBIS was approved for adult patients and launched in the United States and Puerto Ricoin 2013. Anders Ullman, M.D., Ph.D., Vice President of Global Research and Development in Baxter's BioScience business said, "Our focus at Baxter is to strengthen and expand the portfolio of treatments for patients with bleeding disorders, particularly when there are limited treatment options, such as for patients with hemophilia B. We are actively working to extend access to these treatments and look forward to introducing RIXUBIS in Europe and other countries around the world." The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/163d_BAX]
Actavisplc Research Report
On October 31, 2013, Actavisplc (Actavis) confirmed the filing of an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market Isotretinoin Capsules (10 mg, 20 mg, 30 mg and 40 mg).The Company stated that its ANDA product is a generic version of Ranbaxy Inc.'s Absorica®, which is a retinoid indicated for the treatment of severe recalcitrant nodular acne in patients aged 12 years and older. The Company informed that on October 29, 2013Cipher Pharmaceuticals, Inc.,Galephar Pharmaceutical Research, Inc., Ranbaxy, Inc. and Ranbaxy Pharmaceuticals, Inc. filed suit against Actavis, in the U.S. District Court for the District of New Jersey to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent No. 8,367,102. Actavis added that the lawsuit resulted in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs earlier. Actavis informed that based on available information, the Company believes it may be a "first applicant" to file an ANDA for the generic version of Absorica and may be entitled to 180 days of generic market exclusivity, should its ANDA be approved. The Full Research Report on Actavisplc- including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/4997_ACT]
Thermo Fisher Scientific Inc. Research Report
On November 5, 2013, Thermo Fisher Scientific Inc. reported that its company, One Lambda Inc.,has received CE mark approval in Europe for its C1qScreen™ assay. The Company stated that C1qScreen is a solid-phase assay that uses Luminex®-based single antigen beads to allow clinicians to further characterize donor-specific antibodies (DSA), distinguishing complement binding antibodies from non-complement binding antibodies. The Company added that with this information, clinicians can better study the impact of the antibodies on clinical outcomes andthe minimally invasive assay accelerates sample-to-answer times, making it ideal for monitoring antibody progression and desensitization therapy. The Company stated that the assay was recently cited in the New England Journal of Medicine for its use in a kidney graft survival study, and is now available in all CE mark-conforming countries, enabling European HLA clinics and laboratories to immediately use it during transplant diagnostic procedures. The Full Research Report on Thermo Fisher Scientific Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/45ed_TMO]
Becton, Dickinson and Co. Research Report
On November 6, 2013,Becton, Dickinson and Co. (BD)'s business segment, BD Diagnostics, announced that it has achieved CE/IVD marking of its BD TotalysTM MultiProcessor at the EUROGIN 2013 conference. According to the Company, the stated MultiProcessor is an automated instrument that integrates the pre-processing for the BD SurePath™ Liquid-based Pap Test with a molecular aliquot, maintaining sample integrity while improving efficiency in the lab. Paul Holt, Global Market Segment Leader, Women's Health & Cancer - BD Diagnostics stated, "When laboratories and physicians partner with BD Diagnostics, they benefit from highly customized, leading-edge solutions for the rapidly changing landscape of cervical cancer screening." The Full Research Report on Becton, Dickinson and Co.- including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/0175_BDX]
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article